Fertility is expected to be reduced after the extensive chemotherapy and/or radiotherapy that is needed for conditioning prior to bone marrow transplantation. However, a male patient can be fertile, and in very rare situations such as reported here, this may confuse subsequent paternity testing. The patient, initially excluded as the biological father by red cell types but not by HLA, was subsequently included after the history of his previous marrow transplant was revealed, a review of the HLA results and further RFLP testing on buccal mucosal cells. This case points to the need for good history taking before performing paternity testing. Keywords: parentage testing; paternity; allogeneic bone marrow transplant; fertility Although bone marrow transplantation is a therapeutic modality that results in long-term disease-free survival and perhaps cure for many patients with hematological malignancies that would otherwise be fatal, the survivors are faced with many issues that prove to be difficult particularly for younger individuals, over their remaining lifetime. One of these is infertility. The actual incidence of this as a problem is difficult to quantitate, as the denominator of this equation is uncertain, that is to say the number of women who actually wish to conceive is not known and in the case of males, it is not the usual practice to study genetic status of the progeny of a successful conception to determine who actually fathered the child. More has been published on female fertility than on male, as it is clear when the surviving transplant patient has been pregnant and delivered a child. This still remains an uncommon event.
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1,2 In the case of male fertility even less is reported and in only three cases of which we are aware, was the paternity actually determined by genetic typing; one father had received an autologous transplant 3 and the others allogeneic transplants. 4, 5 We now report a case where the paternity of a transplanted man was (eventually) recognised during the course of test- ing in a case of disputed paternity. This appears to be the first report of its kind and underlines the need for paternity testing laboratories to be aware when bone marrow transplants have been performed.
Case report
Paternity testing was requested in 1996 by a 27-year-old man (applicant). In this case, he was attempting to prove his paternity rather than to deny it. He had become involved with a woman who was in the process of separating from her husband. She became pregnant, delivered a healthy child, was not interested in raising it and had it placed in a foster home. The applicant was particularly keen to have custody of the child; however, he was told that he could not do so unless he could show that it was his child. Standard testing was performed including HLA typing, ABO, Rhesus, MNS, Kidd, Duffy and Kell blood groups as well as Factor B and C3 of the complement system. On the basis of these results (Table 1) , although his HLA results were compatible with paternity, he was clearly excluded on the Rhesus, MNS and Kidd systems. This was duly reported. The applicant again approached the testing laboratory with the fact that he had undergone allogeneic bone marrow transplantation in 1988 for acute myeloid leukemia, and he raised the question as to whether this would have any impact on the results of the paternity testing. This information changed the case entirely and indeed explained why the HLA phenotype did not show any exclusions, for he had been given an HLA-matched marrow transplant from his brother. The exclusions on red blood cell types had therefore to be ignored. In relation to the fertility aspect, the applicant had been given busulfan and cyclophosphamide as conditioning at the time of the marrow transplant, rather than a total body irradiation-based regimen. 6 The latter increases the chance of subsequent infertility. 7 A haplotype interpretation of the HLA results is given in Table 1 . It can be seen that the obligatory paternal haplotype for the child is A11, B8. This is compatible with the applicant's HLA phenotype. Two points are of interest here: first, the paternal haplotype A11, B8 is a rare one with a frequency in North American caucasoids of 12/10 000. 8 The statistical chance of a random male's sperm providing this haplotype are thus 0.0012 or 0.12%. The maximum probability that the applicant could have contributed to the obligate paternal haplotype is 0.5. Given that the frequency of the obligate paternal haplotype is 0.0012, the maximum paternity index is 0.5/0.0012 = 416.67, corresponding to a maximum probability of paternity of 99.76%. Consideration of the complement C3 alleles which are not bone marrow dependent, improves these statistics slightly.
A combined paternity index of 534 is reached, and the probability of paternity is 99.81%, both of which are respectable figures for likelihood. The second point of interest is that both the applicant and his brother, the bone marrow donor, were group Apositive and HLA-A, B, DR identical (A11, A28; B8, B62; DR3, DR7). A review of Bone Marrow Donors Worldwide produced in Leiden, The Netherlands, via the quarterly update of potential bone marrow donors across the worldwide network of donor registries, revealed no HLA-A, B, DR matches with the applicant and only 26 possible HLA-A, B matches in over 3.5 million typings listed. Thus, the applicant's HLA phenotype is extremely rare, and this is because all four possible haplotype arrangements are also rare. The pair shown in Table 1 are about twice as common (0.0012 and 0.0015) as the alternative possibility (0.0011, 0.0007).
Unfortunately there was no extensive red cell typing of the father done prior to his transplant, so we have not been able to match his germ line red cell types with those of the child. He was recorded as being group A, Rhesus (D) positive, which is the same that was found during the recent paternity testing. Without a pretransplant blood sample or else DNA level testing on tissues other than those derived from bone marrow (eg sperm or buccal mucosal cells) this final evidence remains unrevealed. The red cell blood types that the applicant now expresses, are those of his brother, and are entrenched in the stem cells of the donated marrow graft.
For the record, the former husband was excluded as the biological father on HLA-A, HLA-B and by his Rhesus alleles. The applicant therefore has a high statistical likelihood of being the father. Indeed, the courts have recently agreed to his taking over the custody of the baby using these data plus some additional testing done in another laboratory on buccal mucosal cells by one of us (JSW). This testing involved the use of the RFLP technique and three VNTR probes D2S44, D4S139 and D5S110. 9 From these three probes, with a prior probability of paternity of 0.5, combined paternity index of 960 and a probability of paternity of 99.89% were derived.
Discussion
This report shows that the patient was fertile some 7 years after bone marrow transplantation, making this as far as we know, the fourth proven case to be reported. The fact that he was then involved in a situation where paternity needed to be established may very well make him unique.
It is well known that absolute proof of paternity is never possible and will remain as a statistical likelihood, since one can never be sure there is not another man, somewhere in the world, who could have provided the correct genes. On the other hand it is stated that exclusion of paternity can be assigned 100% certainty, provided that the blood sample came from the correct man, the tubes were labelled correctly throughout and there were no laboratory errors. To this is often added that the blood typing results can be altered by massive blood transfusions so this is usually excluded by a question on the registration form. This case emphasizes the need to add bone marrow transplantation to the list of conditions that can invalidate the results, and obviously this is applicable to any member of the trio, mother, child and putative father.
Cases such as the one described are extremely rare and are not likely to be seen by the overwhelming majority of geneticists who would be involved in doing the testing. This case does highlight, however, the fact that there are now a number of situations in clinical medicine, where straight forward testing without a history from all those involved may result in the wrong conclusions being drawn, with possible long-term ramifications for both parents and offspring. These situations include artificial insemination using donor sperm, embryo implantation using donor sperm, embryos or eggs, allogeneic bone marrow or peripheral blood stem cell transplantation, and forensic testing where blood or semen samples constitute major aspects of the evidence. We are unaware of any cases where this has actually become an issue. In the present case, the desire of a potential father to undertake the responsibility of raising his child, brought this scenario to a satisfactory conclusion. It does point out the necessity of taking a good clinical history and of seeking information that may not be readily volunteered. It also points to the need for suitable modification of the forms, letter and reports used by laboratories who undertake to do parentage testing, by questions and disclaimers. In the United States, the American Association of Blood Banks guidelines clearly state that 'A history of bone marrow transplantation shall be recorded for each individual tested. 10 
